Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
Healthcare
$0.40 -5.76%
-$0.10 today
- Market cap
- $97.62M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
52W Low $0.16High $3.39
Volume 6.81M
Average 17.46M
Income Statement
Follow revenue through to earnings.
Revenue
$1.41M
FY 2025 · Annual
Operating Income
-$67.06M
FY 2025 · Annual
Net Income
-$62.42M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Sep 2021 | FY 2022 Sep 2022 | FY 2023 Sep 2023 | FY 2024 Sep 2024 | FY 2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K |
| Gross Profit | (262.14K) | (204.69K) | (44.19K) | (113.86K) | 657.21K |
| Gross Margin | — | — | — | — | 46.5% |
| Research & Development | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T |
| Selling, General & Admin | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M |
| Operating Expenses | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| EBITDA | (51.51M) | (64.36M) | (57.38M) | (72.09M) | (63.58M) |
| EBITDA Margin | — | — | — | — | -4497.7% |
| Operating Income | (51.73M) | (63.07M) | (53.13M) | (71.7M) | (67.06M) |
| Operating Margin | — | — | — | — | -4744.3% |
| Interest Income | 0 | 0 | 0 | 906.15K | 89.74K |
| Interest Expense | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K |
| Other Income / Expenses | (1.43M) | (2.98M) | (5.85M) | (3.66M) | 3.08M |
| Income Before Tax | (53.16M) | (66.05M) | (58.98M) | (75.36M) | (63.98M) |
| Pre-Tax Margin | — | — | — | — | -4526.0% |
| Income Tax Expense | 2K | 2.8K | 2.8K | 2.8K | (1.55M) |
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Net Margin | — | — | — | — | -4416.2% |
| EPS (Basic) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| EPS (Diluted) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| 7.63M | 10.6M | 12.51M | 18.55M | 34.8M | |
| 7.63M | 10.6M | 12.51M | 18.55M | 25.48M |
OTLK Earnings Waterfall · TTM
NASDAQ:OTLK · Revenue to Net Income
Key Ratios
EPS$-1.62
Gross Margin313.6%
Net Margin2889.6%
P/E Ratio-0.9
P/S Ratio-77.3
Analysis
$333.1K of revenue converted into -$61.0M of net income for the selected period. Gross margin is 313.6% and net margin is 2889.6%, showing how much revenue survives after costs and taxes. EPS is $-1.62, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 13, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 8-K | Current report | Sep 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 2, 2026 |
How much revenue does OTLK generate?
Outlook Therapeutics, Inc. (OTLK) reported $1.41M of revenue in fiscal 2025.
Is OTLK profitable?
Outlook Therapeutics, Inc. (OTLK) reported -$62.42M of net income, with a net margin of -4416.2%.
Continue the stock analysis
Jump to another research area for this company.